2. Summary of Significant Accounting Policies (Tables)

12 Months Ended

Apr. 30, 2019

Accounting Policies [Abstract]

Disaggregation of revenue

	Fiscal Year Ended April 30,
	2019		2018		2017
Manufacturing revenue	$	43,432	$	47,437	$	52,215
Process development revenue		10,171		6,184		5,415
Total Revenues	$	53,603	$	53,621	$	57,630

Schedule of accounts receivable

	April 30,
	2019		2018
Trade receivables	$	7,374	$	3,539
Other receivables		–		215
Total Accounts receivable	$	7,374	$	3,754

Concentration of revenues

Customer	Geographic Location	2019	2018	2017
Halozyme Therapeutics, Inc.	U.S.	30%	55%	58%
ADC Therapeutics America Inc.	U.S.	21	9	–
Coherus BioSciences, Inc.	U.S.	13	22	26
Other customers	U.S./non-U.S.	36	14	16
Total		100%	100%	100%

Inventories

	April 30,
	2019		2018
Raw materials	$	6,557	$	8,165
Work-in-process		–		7,964
Total Inventories	$	6,557	$	16,129

Schedule of property and equipment

	April 30,
	2019			2018
Leasehold improvements	$	20,574		$	20,686
Laboratory and manufacturing equipment		12,858			10,258
Computer equipment and software		4,644			4,087
Furniture, fixtures and office equipment		528			510
Construction-in-progress		1,590			3,310
Total Property and equipment, gross		40,194			38,851
Less: Accumulated depreciation and amortization		(14,569	)		(12,372	)
Total Property and equipment, net	$	25,625		$	26,479

Impact of the adoption of ASC 606

The cumulative effect of the adoption of ASC 606 on amounts previously reported on the Consolidated Balance Sheet at April 30, 2018 was as follows:

	As Reported April 30, 2018			ASC 606 Transition Adjustment			Balance at May 1, 2018
Contract assets	$	–		$	2,888		$	2,888
Inventories		16,129			(7,871	)		8,258
Contract liabilities		27,935			(7,913	)		20,022
Other current liabilities		905			191			1,096
Accumulated deficit		(559,129	)		2,739			(556,390	)

The impact of the adoption of ASC 606 on the Consolidated Balance Sheet at April 30, 2019 was as follows:

	As Reported		Effect of Adoption Increase/(Decrease)			Balance Without Adoption of ASC 606
Contract assets	$	4,327	$	4,327		$	–
Inventories		6,557		(18,293	)		24,850
Contract liabilities		14,651		(19,771	)		34,422

The impact of the adoption of ASC 606 on the Consolidated Statements of Operations and Comprehensive Loss for the fiscal year ended April 30, 2019 was as follows:

	As Reported			Effect of Adoption Increase/(Decrease)		Balance Without Adoption of ASC 606
Revenues	$	53,603		$	13,243	$	40,360
Cost of revenues		46,379			9,743		36,636
Gross profit		7,224			3,500		3,724
Operating loss		(5,622	)		3,500		(9,122	)
Loss from continuing operations		(5,056	)		3,500		(8,556	)